Bedrijfsoverzicht
Immatics N.V. is a clinical-stage biopharmaceutical enterprise dedicated to the research and development of potential T cell redirecting immunotherapies designed for the treatment of cancer within the United States. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a field characterized by high-risk research phases and significant capital requirements before product commercialization. As of the latest reporting period, the company maintains a market capitalization of $1.40B, generates annual revenue of $48.27M, and employs 589 individuals across its operational footprint. The combination of a $1.40B market cap and $48.27M in revenue indicates that Immatics holds a substantial valuation relative to its current revenue stream, which is typical for biotechnology firms investing heavily in clinical trials before achieving widespread profitability.
Financiële gezondheid
The company reported revenue of $48.27M over the trailing twelve months, while simultaneously posting a net income of $-196,447,008 and an EBITDA of $-172,875,008. The significant divergence between the $48.27M revenue figure and the $-196,447,008 net loss reveals a cost structure where operating expenses, likely driven by research and development expenditures, vastly exceed total sales income. Free cash flow stands at $-128,190,248, indicating that the company is currently burning cash at a rapid pace, which limits immediate financial flexibility for strategic acquisitions or dividend distributions without further capital raising. Despite the negative margins, the company holds $469.34M in cash against $15.63M in debt, creating a substantial liquidity buffer. The debt-to-equity ratio of 3.23 suggests a leveraged balance sheet, yet the massive cash reserve mitigates immediate solvency risks associated with this leverage level. Operating liquidity appears robust given the current ratio of 11.72, which signifies that the company possesses more than eleven times the current assets required to meet its short-term liabilities. Return on Equity is recorded at -37.1% and Return on Assets at -18.1%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in terms of generating profit, a common trait for clinical-stage biotech entities still navigating development hurdles.
Waarderingsbeoordeling
The P/E Ratio (TTM) is listed as N/A due to the negative earnings, while the Forward P/E is calculated at -5.91, implying that the market expects earnings to remain negative or that valuation is being determined through alternative metrics rather than current profitability. The Price to Book ratio stands at 2.50, indicating that the market values the company at two and a half times its book value, which often reflects investor optimism regarding the potential future value of its intellectual property and pipeline assets. The Price to Sales ratio is 28.98 and the EV/EBITDA is -5.47, suggesting that valuation is heavily dependent on future clinical success rather than current financial performance, as traditional profitability-based multiples are distorted by negative EBITDA. The stock has traded between a 52-week high of $12.41 and a 52-week low of $3.94, meaning the current price sits at a premium relative to the lows but remains significantly below the recent peak, reflecting market volatility and sentiment shifts regarding the asset's development progress. The Beta value of 1.34 indicates that the stock price is approximately 34% more volatile than the broader market, exposing investors to heightened risk fluctuations compared to large-cap financial instruments.
Growth & Income
Revenue growth year-over-year has contracted by -64.9%, while earnings growth is N/A due to the absence of profitability; this contraction in revenue suggests a decline in sales or a shift in revenue recognition timing that outpaces any potential earnings recovery. As the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which implies that all available earnings, though currently negative, and the cash reserves are being retained within the organization to fund ongoing research and development activities rather than being distributed to shareholders. The overall growth and income profile for Immatics N.V. is characterized by revenue contraction and a lack of dividend income, with the company's financial strategy focused entirely on sustaining its clinical-stage operations until potential regulatory approval or commercial milestones are achieved.